Author:
Nomura Teiko Komori,Endo Satoshi,Kuwano Takuma,Fukasawa Kazuya,Takashima Shigeo,Todo Tomoki,Furuta Kyoji,Yamamoto Takuhei,Hinoi Eiichi,Koyama Hiroko,Honda Ryo
Abstract
AbstractARL-17477 is a selective neuronal nitric oxide synthase (NOS1) inhibitor that has been used in many preclinical studies since its initial discovery in the 1990s. In the present study, we demonstrate that ARL-17477 exhibits a NOS1-independent pharmacological activity that involves inhibition of the autophagy-lysosomal system and prevents cancer growth in vitro and in vivo. Initially, we screened a chemical compound library for potential anticancer agents, and identified ARL-17477 with micromolar anticancer activity against a wide spectrum of cancers, preferentially affecting cancer stem-like cells and KRAS-mutant cancer cells. Interestingly, ARL-17477 also affected NOS1-knockout cells, suggesting the existence of a NOS1-independent anticancer mechanism. Analysis of cell signals and death markers revealed that LC3B-II, p62, and GABARAP-II protein levels were significantly increased by ARL-17477. Furthermore, ARL-17477 had a chemical structure similar to that of chloroquine, suggesting the inhibition of autophagic flux at the level of lysosomal fusion as an underlying anticancer mechanism. Consistently, ARL-17477 induced lysosomal membrane permeabilization, impaired protein aggregate clearance, and activated transcription factor EB and lysosomal biogenesis. Furthermore, in vivo ARL-17477 inhibited the tumor growth of KRAS-mutant cancer. Thus, ARL-17477 is a dual inhibitor of NOS1 and the autophagy-lysosomal system that could potentially be used as a cancer therapeutic.
Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Dao, V.T.-V. et al. Nitric oxide synthase inhibitors into the clinic at last. In Reactive Oxygen Species: Network Pharmacology and Therapeutic Applications (eds Schmidt, H. H. H. W. et al.) 169–204 (Springer International Publishing, 2021).
2. Zhang, Z. G. et al. ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. 16, 599–604 (1996).
3. Pelligrino, D. A., Santizo, R., Baughman, V. L. & Wang, Q. Cerebral vasodilating capacity during forebrain ischemia: Effects of chronic estrogen depletion and repletion and the role of neuronal nitric oxide synthase. NeuroReport 9, 3285–3291 (1998).
4. O’Neill, M. J. et al. ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Brain Res. 871, 234–244 (2000).
5. Yabuki, Y. et al. Oral L-citrulline administration improves memory deficits following transient brain ischemia through cerebrovascular protection. Brain Res. 1520, 157–167 (2013).